[ad_1]
In a statement, the lab reveals that the vaccine prevents 70 percent of people from developing the disease caused by the new coronavirusbased on interim results of phase 3 tests that demonstrated that The effectiveness resulted from the combination of two dosage regimens: one was 90 percent effective and the other 62 percent.
These are interim results from large-scale clinical trials developed in the UK and Brazil, says AstraZeneca. But in relation to the data already available, this vaccine has a lower effectiveness rate than those of Pfizer / BioNTech or Moderna, which exceed 90 percent.
“The results of an interim analysis of the AZD1222 clinical trials showed that the vaccine was very effective in preventing Covid-19, its main target, and there were no hospitalizations or severe cases of the disease in participants who received the vaccine. A total of 131 cases of Covid-19 were registered in the interim analysis “, read in the AstraZeneca statement.
Researchers involved in the production of this vaccine also noted that the vaccine “It is effective in preventing many people from getting sick and has been shown to work well in different age groups.”
The pharmaceutical company adds that efficacy can be as high as 90 percent “on a dosing regimen.”
“The effectiveness and safety of this vaccine confirm that it will be highly effective against Covid-19 and will have an immediate impact on this public health emergency,” Pascal Soriot, CEO of AstraZeneca, said in the statement.
More than 20,000 volunteers participated, half in the UK and half in Brazil. Among those who received two doses of the vaccine, there were 30 cases of Covid-19 and 101 cases in people who received a sham injection.
When the volunteers received two “high” doses, the protection was 62 percent, but increased to 90 percent when the people received a lower “dose” followed by a high dose. However, it is not yet clear why this difference in effectiveness.
According to the BBC andThese results may be a triumph, but also a disappointment after the results announced by the pharmaceutical companies Pfizer and Moderna proved to be superior.. But nevertheless, Oxford vaccine is much cheaper, easier to store and to reach all corners of the world than the other two, which may mean it will play an important role in fighting the pandemic, if approved by regulators, the British broadcaster said.
Therefore, it is expected that, although the effectiveness percentage of the AstraZeneca vaccine is lower, it will play an important role in the fight against the pandemic, if it is approved by regulators.
Remember it Researchers at the University of Oxford went through the normal process of developing a vaccine, which would take a decade in just ten months.
Preliminary results now published by biopharmaceuticals have not yet been peer-reviewed or published in any scientific journal, something that should happen as soon as the full results of the clinical trials are available. Process that, according to AstraZeneca, is already underway.
